This is more like the slow ride down to hell for longs. This stock is only going lower with interest rates rising on that much debt, BSX will be lucky if they can avoid bankruptcy.
their products are a dime-a-dozen outdated, inferior products, and thats the ones that don't get recalled. Maybe BSX can steal some patents and start a whole new company with a whole new product, before they get hauled back to court.
CONR has a better mousetrap. BSX obsolete.
Conor Medsystems is set to take on Boston Scientific
Medsystems Inc. (CONR ) has developed a new better breed of stent that have the power to swipe large swaths of business from rivals such as Johnson & Johnson (JNJ ) and Boston Scientific Corp. (BSX )
J&J and Boston Scientific are the two gladiators in this field, but many physicians are keeping a close eye on Conor's product as well. Although the stent's rate of restenosis, or recurrence of arterial blockages, has been much better than Boston Scientifics, doctors say Conor's is also easier to implant is also safer and more effective.
The Menlo Park (Calif.) company will release new data from clinical trials at a top cardiovascular meeting in Washington. "If it came out in the U.S. right now, the market would swing," says Dr. Dean Kereiakes, a professor of clinical medicine at Ohio State University who is serving as a co-principal investigator for Conor's U.S. clinical trial.
Conor has had some success but CIBC analyst John P. Calcagnini, who has a $26 price target on the stock, believes Conor can take 11% of the market by 2006.
Angiotech licenses a drug called paclitaxel to Boston Scientific that inhibits the growth of scar tissue. Conor uses the same drug in its clinical trials, but the way it incorporates and releases the drug is novel and doesn't infringe on its rivals' patents.
Litvack has helped run three companies, one of which was Advanced Interventional Systems Inc. The company developed laser technology to clear up artery blockages, In 1994 it was acquired by its chief rival, Spectranetics Corp. (SPNC ), for just $12 million -- a thin sliver of the $150 million market cap it reached after going public in 1991.
At least two physicians with no financial ties to Conor give its device high marks. Some cardiologists say Conor may succeed because its stent, which is thinner and less sticky than existing drug-coated stents, is more easily maneuvered through a clogged artery. "If everything else was me-too, just that one feature would take the whole market," says Dr. Mitchell Krucoff, a professor of medicine and cardiology at Duke University Medical Center If current clinical trials go well, Conor must battle Boston Scientific, J&J, and others. Boston Scientific is spending more than $200 million a year on interest and debt. For Litvack, the key to beating the competition is more innovation, both in devices and drugs. Conor is now developing a stent that uses anti-clotting compounds acquired from Novartis. "We believe the job of a good medical company is to make your products obsolete," he says.
Well it seems obvious BSX products are inferiior and continue to kill people, since doctors are afraid to use them due to litigation, and malpractice suits, BSX will continue to lose money and languish.
Studies Give Edge To J&J Stent
Matthew Herper, 08.16.05, 4:00 PM ET
NEW YORK - Johnson & Johnson has a better product than its rival, Boston Scientific, for holding open clogged arteries.
New data published in the two leading medical journals indicates that patients who receive Cypher, a drug-coated stent made by Johnson & Johnson (nyse: JNJ - news - people ), are less likely to need a repeat surgery than those who get Taxus, a rival stent from Boston Scientific (nyse: BSX - news - people ).
That's more bad news for Boston Scientific, which has seen shares drop 30% since September 2004 amid concerns over its over-reliance on drug-coated stents.
"There is a difference," says David J. Moliterno, a cardiologist at the University of Kentucky who wrote an editorial on the studies in The New England Journal of Medicine.
For all patients taken as a group, Moliterno says, those who receive Taxus are far more likely to need their procedure redone than those who receive Cypher.
High-risk patients, such as those with diabetes, also fare better with the Cypher stent, he says.
Samin Sharma, a cardiologist at the Mount Sinai School of Medicine, say she thinks most doctors would opt to use Cypher if it weren't for persistent manufacturing problems that can make the device harder for doctors to get. He notes that the evidence is consistent that Cypher is better at preventing arteries from reclogging.
The researchers found that patients receiving Cypher were at much lower risk of having their arteries reclose than those who received Taxus. The results are published in the current issue of The Journal of the American Medical Association. Says Firth, "I think the value of this product from a health economics standpoint is very clearly demonstrated."
Meanwhile, J&J says the U.S. Food and Drug Administration has visited new manufacturing plants that would finally allow it to churn out more Cypher stents.
This is too funny, there is sooo much bad news about this travesty of a company, the pumpers get so mad when you post anything about the
class action lawsuits, recalled products, insider selling, numerous patient deaths, losing market share, no growth, huge debt, more lawsuits, defective products, angry employees, failed strategy, missed estimates increasing losses, poor chart, or the FDA problems. These pumping longs are living in denial and keep trying to bury the issues facing BSX.
This stock is a perfect storm of disaster. Class action lawsuits, recalled products, insider selling, numerous patient deaths, losing market share, no growth, huge debt, more lawsuits, defective products, angry employees, failed strategy, missed estimates and losses. It has a long way down. Doubt it holds support at $18.
Anyone dumb enough to buy BSX deserves to lose money. A fool and his money are soon parted. Lawsuits, insider selling, class action lawsuits. Losses, pattent theft. Bearish chart.
Recalls. Yea I want to own this loser ha. Not.
Too many good companies out there that pay dividends. Wait till BSX inherits Guidants lawsuits.
I noticed a trend where the stock is up at the beginning of the day and by the end of the day its down. I think this is a pump and dump.
BOSTON (MarketWatch) - Boston Scientific said early Thursday that it is recalling about 40,000 of its angioplasty devices due to concerns the product may separate during surgical procedures.
Boston Sci. recalls angioplasty devices
Guidant to enter merger talks with Boston Sci.
Drug stocks dip as Millennium slides on downgrade
More news for BSX
Quote & News Charts Financials Analysts Options SEC Filings
In a release, the Natick, Mass.-based medical device maker said that it was recalling all of its Flextome Cutting Balloon Device Monorail and Peripheral Cutting Balloon Microsurgical Dilatation Device Small Monorail delivery systems after receiving complaints about the products.
BSX said that separation of the device can result in lengthened surgeries or the need for additional surgeries.
Boston Scientific said it has alerted the Food and Drug Administration to the recall.
On Dec. 2, Boston Scientific said it was recalling about 18,000 of its Stainless Steel Greenfield(R) Vena Cava Filter with 12Fr Femoral Introducer Systems for defects. The devices are used to help prevent blood clots in the legs from traveling to the lungs, which can be deadly. To date, the company said it had received reports of serious injuries and death related to the defect.